Noopept
clinical trialsAlso known as: Omberacetam, GVS-111
Noopept (Omberacetam, GVS-111) is a synthetic proline-containing dipeptide that functions as a prodrug for cycloprolylglycine (CPG). Its primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and cortex, which enhances synaptic plasticity and neuroprotection. Additionally, Noopept modulates cholinergic and glutamatergic systems, including AMPA receptor activity, and exhibits antioxidant properties by reducing lipid peroxidation. These combined actions produce nootropic (cognitive-enhancing) and anxiolytic effects without significant affinity for common neurotransmitter receptors. Key research findings from clinical trials and preclinical studies indicate that Noopept improves memory acquisition, recall, and resistance to amnestic agents in rodent models. Human trials have shown enhanced cognitive performance in healthy volunteers and patients with organic brain syndromes, with effects comparable to piracetam but at significantly lower doses (10–30 mg/day). Neuroprotective effects have been demonstrated in models of cerebral ischemia and chronic stress, attributed to increased BDNF/NGF signaling and reduced oxidative stress. The compound also exhibits anxiolytic properties in elevated plus-maze and conflict tests. Clinically, Noopept has been investigated for cognitive decline associated with aging, traumatic brain injury, and cerebrovascular disorders. Its favorable safety profile in short-term studies—with mild side effects such as headache or irritability—supports its potential as a therapeutic agent for cognitive enhancement and neuroprotection. However, long-term safety data remain limited, and regulatory approval varies by region. For research purposes only — not medical advice.
Key data
C17H22N2O4Research & studies
Natural compounds like curcumin, Ginkgo biloba, and Rhodiola rosea show cognitive benefits, with research ongoing into nanoformulation delivery.; Synthetic enhancers such as Modafinil, Piracetam, and Noopept demonstrate promise in improving cognitive functions.; Behavioral interventions including sleep optimization, meditation, and physical exercise are evaluated for cognitive enhancement.; Noninvasive brain stimulation (TMS, tDCS) and innovative methods like whole-body vibration and brain-machine interfaces are explored.
Noopept increases basal and induced DNA-binding activity of HIF-1 in SH-SH5Y cells.; Noopept stabilizes HIF1 by inhibiting HIF-1 prolyl hydroxylase.; Noopept positively affects HIF1 protein levels.; Noopept alters expression of genes controlled by HIF-1 across different metabolic pathways.
Noopept normalized delayed puberty in diabetic rats (p < 0.05).; Blood glucose levels were lower in noopept-administered diabetic groups (p < 0.05).; Noopept decreased HOMA-IR in insulin-treated diabetic rats (p < 0.05).; No significant differences were found in spatial learning or hippocampal NGF/BDNF levels among groups.
Frequently asked questions
What is Noopept?
Noopept (Omberacetam, GVS-111) is a synthetic proline-containing dipeptide that functions as a prodrug for cycloprolylglycine (CPG). Its primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and cortex, which enhances synaptic pla
How does Noopept work?
Proline-containing dipeptide prodrug of cycloprolylglycine; increases BDNF/NGF expression with nootropic and anxiolytic effects.
What is the research status of Noopept?
Noopept is currently classified as clinical trials, with 83 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Noopept?
Noopept has a molecular weight of approximately 318.4 g/mol (formula C17H22N2O4).
Related peptides
CNTF-derived peptidergic compound that promotes neurogenesis and reduces tau pathology in preclinical Alzheimer's models.
33-aa hypothalamic neuropeptide acting on OX1/OX2 receptors to promote wakefulness and arousal.
Porcine brain-derived peptide preparation with neurotrophic-factor-like activity studied in stroke, TBI, and dementia.
Ligand for NPSR1 . Binds to its receptor with nanomolar affinity and initiates a G /GNAQ-dependent phospholipase C-activating signaling pathway. This results in Ca mobilization from intracellular stores and increased int…
NCAM-derived FG-loop peptide that activates FGFR1 to enhance synaptic plasticity and memory in animal models.
May function as an output molecule from the suprachiasmatic nucleus that transmits behavioral circadian rhythm.
Build on Noopept data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key